Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity - Takeaways - MDSpire

Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity

  • By

  • Qi-Qing Zhang

  • Xin-Xin Luo

  • Hua Chen

  • Wei Wang

  • Jun Liu

  • Ying Li

  • Hong-Li Qiao

  • Lang Chen

  • Zheng-Quan Feng

  • May 1, 2026

  • 0 min

Share

  • 1

    A 58-year-old male with advanced squamous cell lung carcinoma developed grade 3 immune-mediated myocarditis after chemoimmunotherapy.

  • 2

    Following recovery from myocarditis, the patient received second- and third-line treatments, achieving 31 months of progression-free survival.

  • 3

    The case highlights the potential for prolonged overall survival in patients with severe immune-related cardiotoxicity through personalized treatment.

  • 4

    Anti-angiogenic therapy with anlotinib was safely administered after recovery from severe cardiotoxicity, contributing to disease control.

  • 5

    This case underscores the need for further research on optimal post-ICI strategies for patients experiencing severe immune-related adverse events.

Original Source(s)

Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity

  • by Qi-Qing Zhang, Xin-Xin Luo, Hua Chen, Wei Wang, Jun Liu, Ying Li, Hong-Li Qiao, Lang Chen, Zheng-Quan Feng

  • May 1, 2026

Related Content

Non-histone lactylation in cancer: current advances and clinical implications

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Editorial: Early detection, cancer interception, et al.: translating the multifaceted use of liquid biopsy to the management of early disease